Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, everyone, and welcome to the Karis Life Sciences Q2 2026 earnings call. My name is Tanya, and I'll be your conference operator today. All participants are in a listen-only mode. After the prepared remarks, there will be a question-and-answer session. As a reminder, this call is being recorded. I would now like to hand the call over to Russel Denton at Karis. Please go ahead. Thank you. Earlier today, Karis Life Sciences released financial results for the quarter ended June 30th, 2026. Joining from Karis today are David Dean Halbert, our founder, chairman, and CEO, David Spetzler, our president, Brian Brille, our vice chairman and EVP, and Luke Power, our CFO. Before you begin, I'd like to remind you that during this call, management will make forward-looking statements within the meeting of federal securities laws. These statements are based on management's current expectations and involve risks and uncertainties that could cause actual results to materially differ from those anticipated. For a discussion of the factors that could affect our future results, please refer to our SEC filings, including our annual report on Form 10-K and our quarterly reports on Form 10-Q. We undertake no obligation to update these statements except as required by law. This call will also include a discussion of non-GAAP financial measures, which are adjusted to exclude certain specified items The reconciliation of these non-GAAP measures to the most directly comparable GAAP measures are provided in today's earnings release. A copy of today's presentation materials can be found on our investor relations website. I'll now turn the call over to our founder, chairman, and CEO, David Dean Halbert. David? Thanks, Russ, and thanks to everyone for joining. I want to start by highlight...